CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $225,009 | +6.3% | 4,008 | -14.3% | 0.13% | 0.0% |
| Q1 2023 | $211,631 | -1.8% | 4,679 | -11.7% | 0.13% | -10.9% |
| Q4 2022 | $215,486 | -93.9% | 5,301 | -90.2% | 0.15% | -93.9% |
| Q3 2022 | $3,525,000 | +679.9% | 53,944 | +625.8% | 2.43% | +653.7% |
| Q2 2022 | $452,000 | -1.1% | 7,432 | +2.1% | 0.32% | +11.0% |
| Q1 2022 | $457,000 | -28.9% | 7,278 | -14.3% | 0.29% | -26.6% |
| Q4 2021 | $643,000 | -0.2% | 8,489 | +47.6% | 0.40% | -6.6% |
| Q3 2021 | $644,000 | -30.3% | 5,750 | +0.8% | 0.42% | -25.5% |
| Q2 2021 | $924,000 | +63.8% | 5,707 | +23.3% | 0.57% | +55.6% |
| Q1 2021 | $564,000 | -12.7% | 4,630 | +9.8% | 0.36% | -17.4% |
| Q4 2020 | $646,000 | +101.9% | 4,218 | +10.1% | 0.44% | +71.3% |
| Q3 2020 | $320,000 | +19.0% | 3,830 | +4.7% | 0.26% | +15.7% |
| Q2 2020 | $269,000 | – | 3,657 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |